PA
VIR icon

Profund Advisors’s Vir Biotechnology VIR Stock Holding History

Profund Advisors’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$572K Buy
63,866
+7,173
+13% +$57.2K 0.02% 506
2025
Q4 		$342K Buy
56,693
+29,033
+105% +$173K 0.01% 784
2025
Q3 		$158K Sell
27,660
-2,516
-8% -$12.9K 0.01% 1012
2025
Q2 		$152K Sell
30,176
-7,749
-20% -$41.5K 0.01% 941
2025
Q1 		$246K Buy
37,925
+10,415
+38% +$92.6K 0.01% 794
2024
Q4 		$202K Sell
27,510
-9,954
-27% -$78.5K 0.01% 1010
2024
Q3 		$281K Buy
37,464
+7,336
+24% +$63.7K 0.01% 842
2024
Q2 		$268K Sell
30,128
-40,998
-58% -$393K 0.01% 787
2024
Q1 		$721K Buy
71,126
+2,343
+3% +$23.9K 0.03% 452
2023
Q4 		$692K Sell
68,783
-22,255
-24% -$203K 0.03% 417
2023
Q3 		$853K Buy
91,038
+31,029
+52% +$443K 0.05% 319
2023
Q2 		$1.47M Buy
60,009
+910
+2% +$22.9K 0.08% 214
2023
Q1 		$1.38M Buy
59,099
+45,932
+349% +$1.17M 0.09% 203
2022
Q4 		$333K Sell
13,167
-245
-2% -$6K 0.02% 583
2022
Q3 		$259K Sell
13,412
-83
-0.6% -$2.11K 0.02% 661
2022
Q2 		$344K Buy
13,495
+2,584
+24% +$60.3K 0.02% 559
2022
Q1 		$281K Sell
10,911
-1,196
-10% -$35.5K 0.01% 992
2021
Q4 		$507K Sell
12,107
-1,513
-11% -$59.3K 0.02% 604
2021
Q3 		$593K Buy
13,620
+537
+4% +$23.2K 0.02% 549
2021
Q2 		$619K Sell
13,083
-43
-0.3% -$1.96K 0.02% 548
2021
Q1 		$673K Sell
13,126
-1,253
-9% -$67.5K 0.03% 442
2020
Q4 		$385K Buy
14,379
+1,377
+11% +$44.8K 0.02% 675
2020
Q3 		$446K Buy
+13,002
New +$560K 0.02% 490

Other funds holding VIR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
GP
GSK plc London $599M AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Profund Advisors's VIR Position: Q1 2026 in Review

Profund Advisors increased its Vir Biotechnology (VIR) stake by 13% in Q1 2026, buying an estimated $57.2K and bringing the position to 63,866 shares worth $572K. The position accounts for 0.02% of the portfolio, ranked #506.

Profund Advisors first reported a position in VIR in Q3 2020 and has held it in 23 quarters since. The position peaked at $1.47M in Q2 2023. 251 funds tracked by Wall St. Rank hold VIR as of Q1 2026.

  • Profund Advisors held 63,866 shares of Vir Biotechnology worth $572K as of Q1 2026.
  • Profund Advisors bought 7,173 Vir Biotechnology shares in Q1 2026, an estimated $57.2K.
  • Vir Biotechnology made up 0.02% of Profund Advisors's portfolio in Q1 2026, its #506 holding.
  • Profund Advisors first reported a position in Vir Biotechnology in Q3 2020 and has held it in 23 quarters since.
  • Profund Advisors's Vir Biotechnology position peaked at $1.47M in Q2 2023.
  • 251 funds tracked by Wall St. Rank held Vir Biotechnology as of Q1 2026.

Based on Profund Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.